Skip to main content
UniHealth

Doctor search

Caely A Yanikoglu, MD

Dermatology · Stanford

NPI 1306371679

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
1 carrier
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

12 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yanikoglu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A156873 · Current

Licensed to practise in California · since 2018 · expires 2028-07-31 · Columbia University College of Physicians and Surgeons.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$49,928

Medicare paid this office $49,928 for 358 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)138$12,184$73
Short return visit (20+ min)167$9,548$47
Destruction of precancer skin growth, 1 growth148$6,912$40
New patient visit (45+ min)47$5,030$107
Destruction of skin growth, 1-14 growths48$3,297$59
See all 11 services
Every Original Medicare service billed
Return visit (30+ min)138$12,184$73
Short return visit (20+ min)167$9,548$47
Destruction of precancer skin growth, 1 growth148$6,912$40
New patient visit (45+ min)47$5,030$107
Destruction of skin growth, 1-14 growths48$3,297$59
New patient visit (30+ min)34$2,033$60
Biopsy of related skin growth, first growth80$1,812$20
Destruction of precancer skin growth, 15 or more growths17$1,592$76
Destruction of precancer skin growth, 2-14 growths108$900$1
Biopsy of related skin growth, each additional growth25$624$18
Injection into skin growth, 1-7 growths12$405$18

Procedures Medicare counted

Procedure volume Medicare published
Melanoma (skin cancer) excision11More than 64% of doctors who do this
Removal of skin lesions1081More than 94% of doctors who do this
Removal or shaving of skin growth1-10None
Skin biopsy328More than 92% of doctors who do this

Who their Medicare patients are

358 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 17% · Women 56% · Also on Medicaid 12% · Health risk score 1.17. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 61% · Chronic kidney disease 26% · Coronary heart disease 23% · Diabetes 19% · Cancer 16% · Depression 16% · Atrial fibrillation 13% · Heart failure 12% · Stroke 9% · COPD 8% · Dementia 5%.

The office billed $249,028, Medicare allowed $76,843 and paid $49,928; for 1,533 services of 26 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243581,533751.17$249,028$49,928
20234622,254741.03$358,984$85,728
20224222,293741.11$371,261$83,127
202175363741.39$48,959$11,125

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 14 services

Original Medicare services billed in 2023
Return visit (30+ min)166$19,786$81
Short return visit (20+ min)218$15,409$54
Destruction of precancer skin growth, 1 growth182$10,618$45
New patient visit (45+ min)93$9,975$107
Destruction of skin growth, 1-14 growths78$5,687$59
New patient visit (30+ min)79$5,473$69
Destruction of precancer skin growth, 15 or more growths25$3,530$93
Biopsy of related skin growth, first growth111$2,929$23
Long return visit (40+ min)13$1,941$121
Destruction of precancer skin growth, 2-14 growths131$1,505$2
Biopsy of related skin growth, each additional growth37$1,166$19
Injection into skin growth, 1-7 growths16$715$24
Punch biopsy, first skin growth16$586$37
Short return visit14$434$29

2022: 13 services

Original Medicare services billed in 2022
Short return visit (20+ min)189$14,685$55
Return visit (30+ min)107$13,115$81
New patient visit (45+ min)95$10,456$110
New patient visit (30+ min)144$9,287$64
Destruction of precancer skin growth, 1 growth155$9,014$41
Destruction of skin growth, 1-14 growths101$7,225$57
Destruction of precancer skin growth, 15 or more growths33$3,733$87
Biopsy of related skin growth, first growth124$3,353$22
Biopsy of related skin growth, each additional growth60$2,046$19
Destruction of precancer skin growth, 2-14 growths127$1,564$2
Punch biopsy, first skin growth26$976$38
New patient visit (15+ min)11$436$40
Punch biopsy, each additional skin growth13$345$23

2021: 9 services

Original Medicare services billed in 2021
New patient visit (45+ min)16$1,904$119
New patient visit (30+ min)25$1,741$70
Destruction of precancer skin growth, 1 growth30$1,335$45
Short return visit (20+ min)21$1,226$58
Destruction of skin growth, 1-14 growths20$1,225$61
Return visit (30+ min)12$1,076$90
Biopsy of related skin growth, first growth36$778$22
Biopsy of related skin growth, each additional growth15$464$19
Destruction of precancer skin growth, 2-14 growths25$297$2

Drugs they prescribed that Part D paid

$562,566

Pharmacies billed $562,566 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 700) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

590 generic and 110 brand-name prescriptions · $562,566 in drug cost · 14 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Skyrizi14$273,843$19,560
Dupixent52$186,640$3,589
Jublia19$14,243$750
Clobetasol Propionate64$3,097$48
Fluorouracil28$2,466$88
See all 16 drugs
Every Part D drug this clinician prescribed
Skyrizi14$273,843$19,560
Dupixent52$186,640$3,589
Jublia19$14,243$750
Clobetasol Propionate64$3,097$48
Fluorouracil28$2,466$88
Ketoconazole92$1,591$17
Fluocinonide47$1,352$29
Tacrolimus14$973$69
Ciclopirox20$690$34
Triamcinolone Acetonide55$606$11
Hydrocortisone77$466$6
Minoxidil23$422$18
Gabapentin20$352$18
Mupirocin32$287$9
Nystatin11$184$17
Finasteride12$160$13

Year by year

Part D prescribing by year
20247002180% (0)16%$562,566
20231,0203060% (0)9%$569,930
20227622630% (0)None$148,391
2021186880% (0)None$7,677
202065330% (0)None$3,348
201978300% (0)None$40,417

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 19 drugs

Part D drugs prescribed in 2023
Skyrizi16$353,001$22,063
Dupixent12$45,721$3,810
Tacrolimus30$5,770$192
Fluocinonide88$4,751$54
Fluorouracil43$3,734$87
Ketoconazole133$3,723$28
Clobetasol Propionate66$2,973$45
Calcipotriene12$2,616$218
Betamethasone Diprop Augmented16$1,902$119
Metronidazole19$1,511$80
Ciclopirox34$1,508$44
Triamcinolone Acetonide84$1,205$14
Hydrocortisone155$957$6
Doxycycline Hyclate30$950$32
Clindamycin Phosphate21$644$31
Mupirocin49$384$8
Gabapentin20$307$15
Nystatin15$220$15
Finasteride14$195$14

2022: 16 drugs

Part D drugs prescribed in 2022
Fluorouracil72$8,833$123
Fluocinonide65$3,633$56
Betamethasone Diprop Augmented19$2,190$115
Clobetasol Propionate28$1,979$71
Ketoconazole95$1,955$21
Doxycycline Hyclate33$1,387$42
Fluocinolone Acetonide18$1,067$59
Hydrocortisone132$1,016$8
Triamcinolone Acetonide72$918$13
Ciclopirox16$857$54
Clindamycin Phosphate19$757$40
Doxepin11$603$55
Mupirocin26$274$11
Gabapentin12$186$15
Prednisone11$48$4
Finasteride13$46$4

2021: 5 drugs

Part D drugs prescribed in 2021
Clobetasol Propionate20$1,290$65
Ketoconazole25$494$20
Triamcinolone Acetonide26$419$16
Prednisone13$201$15
Hydrocortisone18$124$7

Money from drug and device companies

$31 in 2023

Industry payments by year
202312None$31
202111None$46
202011None$29
201912None$243

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerCibinqo$31
2 payments
  • Education for Cibinqo · 2023-05-10 · $15
  • Education for Cibinqo · 2023-04-12 · $15
See all 2 published payments
Every published payment
PfizerEducation · 2023-05-10Cibinqo$15
PfizerEducation · 2023-04-12Cibinqo$15
See earlier years (2021, 2020, 2019)

2021: $46

Payments by company in 2021
AbbVieHumira$46
1 payment
  • Meals for Humira · 2021-01-21 · $46

2020: $29

Payments by company in 2020
AbbVieSkyrizi$29
1 payment
  • Meals for Skyrizi · 2020-11-20 · $29

2019: $243

Payments by company in 2019
Regeneron Healthcare SolutionsDupixent$243
2 payments
  • Meals for Dupixent · 2019-06-27 · $125
  • Meals for Dupixent · 2019-02-15 · $118

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1306371679
Licence
CA A156873California A156873: Current · expires 2028-07-31
Trained
Columbia University College of Physicians and Surgeons, 2017
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2017-04-25
NPI last updated
2021-11-03
NPI record certified
2021-11-03

This is when the NPI record was last certified, not a medical board exam.